Does the Addition of Cetuximab to Radiochemotherapy Improve Outcome of Patients with Locally Advanced Rectal Cancer? Long-Term Results from Phase II Trials
المؤلفون المشاركون
Kripp, M.
Horisberger, K.
Mai, S.
Kienle, P.
Gaiser, T.
Post, S.
Wenz, F.
Merx, K.
Hofheinz, R.-D.
المصدر
Gastroenterology Research and Practice
العدد
المجلد 2015، العدد 2015 (31 ديسمبر/كانون الأول 2015)، ص ص. 1-8، 8ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2015-03-15
دولة النشر
مصر
عدد الصفحات
8
التخصصات الرئيسية
الملخص EN
Purpose.
The addition of cetuximab to radiochemotherapy (RCT) failed to improve complete response rates in locally advanced rectal cancer (LARC).
We report the long-term results in patients treated within two sequential clinical trials.
Methods.
Patients receiving neoadjuvant RCT using capecitabine and irinotecan (CapIri) within a phase I/II trial or CapIri + cetuximab within a phase II trial were evaluated for analysis of disease-free survival (DFS) and overall survival (OS).
KRAS exon 2 mutational status had been analyzed in patients receiving cetuximab.
Results.
37 patients from the CapIri trial and 49 patients from the CapIri-cetuximab treatment group were evaluable.
Median follow-up time was 75.2 months.
The 5-year DFS rate was 82% (CapIri) and 79% (CapIri-cetuximab) ( P = 0.62 ) .
The median OS was 127.4 months.
5-year OS was 73% for both groups (CapIri and CapIri-cetuximab) ( P = 0.61 ) .
No significant difference in DFS ( P = 0.86 ) or OS ( P = 0.39 ) was noticed between patients receiving CapIri and those receiving CapIri-cetuximab with KRAS wild-type tumors.
Conclusions.
As the addition of cetuximab did not improve neither DFS nor OS it should not play a role in the perioperative treatment of patients with LARC, not even of patients with (K)RAS WT tumors.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Kripp, M.& Horisberger, K.& Mai, S.& Kienle, P.& Gaiser, T.& Post, S.…[et al.]. 2015. Does the Addition of Cetuximab to Radiochemotherapy Improve Outcome of Patients with Locally Advanced Rectal Cancer? Long-Term Results from Phase II Trials. Gastroenterology Research and Practice،Vol. 2015, no. 2015, pp.1-8.
https://search.emarefa.net/detail/BIM-1063946
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Kripp, M.…[et al.]. Does the Addition of Cetuximab to Radiochemotherapy Improve Outcome of Patients with Locally Advanced Rectal Cancer? Long-Term Results from Phase II Trials. Gastroenterology Research and Practice No. 2015 (2015), pp.1-8.
https://search.emarefa.net/detail/BIM-1063946
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Kripp, M.& Horisberger, K.& Mai, S.& Kienle, P.& Gaiser, T.& Post, S.…[et al.]. Does the Addition of Cetuximab to Radiochemotherapy Improve Outcome of Patients with Locally Advanced Rectal Cancer? Long-Term Results from Phase II Trials. Gastroenterology Research and Practice. 2015. Vol. 2015, no. 2015, pp.1-8.
https://search.emarefa.net/detail/BIM-1063946
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1063946
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر